Economic Analysis of Cinacalcet in Combination With Low-Dose Vitamin D Versus Flexible-Dose Vitamin D in Treating Secondary Hyperparathyroidism in Hemodialysis Patients (Q42856989)

From Wikidata

Jump to navigation Jump to search

scientific article published on October 15, 2010

Language	Label	Description	Also known as
English	Economic Analysis of Cinacalcet in Combination With Low-Dose Vitamin D Versus Flexible-Dose Vitamin D in Treating Secondary Hyperparathyroidism in Hemodialysis Patients	scientific article published on October 15, 2010

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

8 November 2017

Economic analysis of cinacalcet in combination with low-dose vitamin D versus flexible-dose vitamin D in treating secondary hyperparathyroidism in hemodialysis patients (English)

1 reference

Europe PubMed Central

PubMed publication ID

8 November 2017

Economic Analysis of Cinacalcet in Combination With Low-Dose Vitamin D Versus Flexible-Dose Vitamin D in Treating Secondary Hyperparathyroidism in Hemodialysis Patients (English)

1 reference

10.1053/J.AJKD.2010.07.012

https://api.crossref.org/works/10.1053/J.AJKD.2010.07.012

3 August 2024

0 references

0 references

hyperparathyroidism

1 reference

based on heuristic

inferred from title

secondary hyperparathyroidism

1 reference

based on heuristic

inferred from title

James B Wetmore

3

object named as

James B. Wetmore

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20951487

3 August 2024

L. Darryl Quarles

6

object named as

L. Darryl Quarles

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20951487

3 August 2024

author name string

Ammar Almehmi

2

1 reference

Europe PubMed Central

PubMed publication ID

8 November 2017

John Lu

4

1 reference

Europe PubMed Central

PubMed publication ID

8 November 2017

Mark Pregenzer

5

1 reference

Europe PubMed Central

PubMed publication ID

8 November 2017

Theresa I. Shireman

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20951487

3 August 2024

language of work or name

1 reference

National Center for Biotechnology Information

PubMed publication ID

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20951487

3 August 2024

publication date

15 October 2010

1 reference

Europe PubMed Central

PubMed publication ID

8 November 2017

full work available at URL

https://api.elsevier.com/content/article/PII:S0272638610011819?httpAccept=text/xml

1 reference

10.1053/J.AJKD.2010.07.012

https://api.crossref.org/works/10.1053/J.AJKD.2010.07.012

3 August 2024

https://api.elsevier.com/content/article/PII:S0272638610011819?httpAccept=text/plain

1 reference

10.1053/J.AJKD.2010.07.012

https://api.crossref.org/works/10.1053/J.AJKD.2010.07.012

3 August 2024

American Journal of Kidney Diseases

1 reference

Europe PubMed Central

PubMed publication ID

8 November 2017

56

1 reference

Europe PubMed Central

PubMed publication ID

8 November 2017

6

1 reference

Europe PubMed Central

PubMed publication ID

8 November 2017

1108-1116

1 reference

Europe PubMed Central

PubMed publication ID

8 November 2017

Hyperparathyroidism in the hemodialysis population: a survey of 612 patients

1

1 reference

10.1053/J.AJKD.2010.07.012

https://api.crossref.org/works/10.1053/J.AJKD.2010.07.012

3 August 2024

Secondary hyperparathyroidism: review of the disease and its treatment.

2

1 reference

10.1053/J.AJKD.2010.07.012

https://api.crossref.org/works/10.1053/J.AJKD.2010.07.012

3 August 2024

K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease

3

1 reference

10.1053/J.AJKD.2010.07.012

https://api.crossref.org/works/10.1053/J.AJKD.2010.07.012

3 August 2024

Prospective trial of pulse oral versus intravenous calcitriol treatment of hyperparathyroidism in ESRD

5

1 reference

10.1053/J.AJKD.2010.07.012

https://api.crossref.org/works/10.1053/J.AJKD.2010.07.012

3 August 2024

Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study

6

1 reference

10.1053/J.AJKD.2010.07.012

https://api.crossref.org/works/10.1053/J.AJKD.2010.07.012

3 August 2024

Development of adynamic bone in patients with secondary hyperparathyroidism after intermittent calcitriol therapy

7

1 reference

10.1053/J.AJKD.2010.07.012

https://api.crossref.org/works/10.1053/J.AJKD.2010.07.012

3 August 2024

The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism

8

1 reference

10.1053/J.AJKD.2010.07.012

https://api.crossref.org/works/10.1053/J.AJKD.2010.07.012

3 August 2024

The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease.

9

1 reference

10.1053/J.AJKD.2010.07.012

https://api.crossref.org/works/10.1053/J.AJKD.2010.07.012

3 August 2024

Cinacalcet HCl and concurrent low-dose vitamin D improves treatment of secondary hyperparathyroidism in dialysis patients compared with vitamin D alone: the ACHIEVE study results

10

1 reference

10.1053/J.AJKD.2010.07.012

https://api.crossref.org/works/10.1053/J.AJKD.2010.07.012

3 August 2024

Meta-analysis of biochemical and patient-level effects of calcimimetic therapy

11

1 reference

10.1053/J.AJKD.2010.07.012

https://api.crossref.org/works/10.1053/J.AJKD.2010.07.012

3 August 2024

A clinician's guide to correct cost-effectiveness analysis: think incremental not average

15

1 reference

10.1053/J.AJKD.2010.07.012

https://api.crossref.org/works/10.1053/J.AJKD.2010.07.012

3 August 2024

Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy

17

1 reference

10.1053/J.AJKD.2010.07.012

https://api.crossref.org/works/10.1053/J.AJKD.2010.07.012

3 August 2024

Differential effects of paricalcitol and calcitriol on intestinal calcium absorption in hemodialysis patients

18

1 reference

10.1053/J.AJKD.2010.07.012

https://api.crossref.org/works/10.1053/J.AJKD.2010.07.012

3 August 2024

Incidence and risk factors for hip or other bone fractures among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study.

19

1 reference

10.1053/J.AJKD.2010.07.012

https://api.crossref.org/works/10.1053/J.AJKD.2010.07.012

3 August 2024

Calcium, phosphorus, parathyroid hormone, and cardiovascular disease in hemodialysis patients: the USRDS waves 1, 3, and 4 study

20

1 reference

10.1053/J.AJKD.2010.07.012

https://api.crossref.org/works/10.1053/J.AJKD.2010.07.012

3 August 2024

Mineral metabolism, mortality, and morbidity in maintenance hemodialysis

21

1 reference

10.1053/J.AJKD.2010.07.012

https://api.crossref.org/works/10.1053/J.AJKD.2010.07.012

3 August 2024

Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns Study

22

1 reference

10.1053/J.AJKD.2010.07.012

https://api.crossref.org/works/10.1053/J.AJKD.2010.07.012

3 August 2024

PTH and the risks for hip, vertebral, and pelvic fractures among patients on dialysis.

24

1 reference

10.1053/J.AJKD.2010.07.012

https://api.crossref.org/works/10.1053/J.AJKD.2010.07.012

3 August 2024

Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism

25

1 reference

10.1053/J.AJKD.2010.07.012

https://api.crossref.org/works/10.1053/J.AJKD.2010.07.012

3 August 2024

Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism caused by chronic kidney disease

26

1 reference

10.1053/J.AJKD.2010.07.012

https://api.crossref.org/works/10.1053/J.AJKD.2010.07.012

3 August 2024

Implementation of 'K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease' after the introduction of cinacalcet in a population of patients on chronic haemodialysis

27

1 reference

10.1053/J.AJKD.2010.07.012

https://api.crossref.org/works/10.1053/J.AJKD.2010.07.012

3 August 2024

Consistent control of mineral and bone disorder in incident hemodialysis patients

28

1 reference

10.1053/J.AJKD.2010.07.012

https://api.crossref.org/works/10.1053/J.AJKD.2010.07.012

3 August 2024

The cost-utility of cinacalcet in addition to standard care compared to standard care alone for secondary hyperparathyroidism in end-stage renal disease: a UK perspective

29

1 reference

10.1053/J.AJKD.2010.07.012

https://api.crossref.org/works/10.1053/J.AJKD.2010.07.012

3 August 2024

The effectiveness and cost-effectiveness of cinacalcet for secondary hyperparathyroidism in end-stage renal disease patients on dialysis: a systematic review and economic evaluation

30

1 reference

10.1053/J.AJKD.2010.07.012

https://api.crossref.org/works/10.1053/J.AJKD.2010.07.012

3 August 2024

Identifiers

10.1053/J.AJKD.2010.07.012

1 reference

Europe PubMed Central

PubMed publication ID

8 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

8 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42856989&oldid=2220095053"